Antiangiogenic Activity of Orally Absorbable Heparin Derivative in Different Types of Cancer Cells

Lee, Dong Yun; Lee, Sung Won; Kim, Sang Kyoon; Lee, Myungjin; Chang, Hyo Won; Moon, Hyun Tae; Byun, Youngro; Kim, Sang Yoon

doi:10.1007/s11095-009-9989-9

Cited by 22 publications

(16 citation statements)

References 41 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only few studies have been reported with an aim of developing heparin-based materials with more specific bioactivities and reduced side effects; integration of the extensive work on the biological activity of specific heparin isoforms [124-126] could significantly benefit biomaterials-related investigations, as the targeting and antitumor roles of heparin could be more extensively exploited in materials design. The use of other stimuli such as light and mechanical force, for triggered action of heparin-based hydrogels, would permit improved spatial and temporal control of hydrogel degradation, which could, for growth-factor-sequestering gels, also yield concomitant benefits of manipulating local release of cytokines, stimulating matrix production by cells, and encouraging tissue regeneration [127, 128].…”

Section: Discussionmentioning

confidence: 99%

Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications

2014

View full text Add to dashboard Cite

Heparin plays an important role in many biological processes, via its interaction with various proteins, and hydrogels and nanoparticles comprising heparin exhibit attractive properties such as anticoagulant activity, growth factor binding, as well as antiangiogenic and apoptotic effects, making them great candidates for emerging applications. Accordingly, this review summarizes recent efforts in the preparation of heparin-based hydrogels and formation of nanoparticles, as well as the characterization of their properties and applications. The challenges and future perspectives for heparin-based materials are also discussed. Prospects are promising for heparin-containing polymeric biomaterials in diverse applications ranging from cell carriers for promoting cell differentiation to nanoparticle therapeutics for cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications

2014

View full text Add to dashboard Cite

show abstract

“…However, heparin has a limitation in clinical uses for cancer treatment, due to its high anti-coagulant activity. Consequently, our previous studies have been trying to minimize the anti-coagulant activity, while increasing the anti-cancer activity by chemical modification [23][24][25][26]. Finally, we discovered that LHT7 might potentially be the most promising angiogenesis inhibitor [24].…”

Section: Discussionmentioning

confidence: 99%

“…We have developed the library of heparin derivatives that have high anti-angiogenic activity and low anti-coagulant activity [23][24][25][26]. Recently, LMWH-taurocholate conjugate (LHT7) showed most promising results, as a novel angiogenesis inhibitor [24].…”

Section: Introductionmentioning

confidence: 99%

Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor

Adulnirath

Chung

Park

et al. 2012

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

“…Nonanticoagulant heparin S-NACH was also found to inhibit pancreatic cancer cell adhesion and metastasis [79]. In an animal study, heparin derivate showed anticancer and antiangiogenic effects [80]. Given the important role of stromal microenvironment in maintenance of pancreatic cancer, these agents might have potential use in the management of this resistant disease.…”

Section: Heparin-derivative Agentsmentioning

confidence: 99%

Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy

Chiu¹,

Wong²,

Leung³

et al. 2014

The Oncologist

View full text Add to dashboard Cite

The progress in the development of systemic treatment for advanced pancreatic cancer (APC) has been slow. The mainstream treatment remains using chemotherapy including gemcitabine, FOLFIRINOX, and nab-paclitaxel. Erlotinib is the only approved biological therapy with marginal benefit. Studies of agents targeting epidermal growth factor receptor, angiogenesis, and RAS signaling have not been satisfying, and the usefulness of targeted therapy in APC is uncertain. Understanding in molecular processes and tumor biology has opened the door for new treatment strategies such as targeting insulin-like growth factor 1 receptor, transforming growth factor b, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Notch pathway. New directions also include the upcoming immunotherapy and many novel agents that act on the microenvironment. The practice of personalized medicine using predictive biomarkers and pharmacogenomics signatures may also enhance the effectiveness of existing treatment. Future treatment approaches may involve comprehensive genomic assessment of tumor and integrated combinations of multiple agents to overcome treatment resistance. The Oncologist 2014;19:937-950 Implications for Practice: Pancreatic cancer is a dismal disease with an unmet need for novel treatment approaches. This paper provides a comprehensive review in the current development of new treatment strategies, supported with concise scientific background and brief descriptions of ongoing phase II/III clinical trials. It provides both nonspecialists and specialists in pancreatic cancer care an overview of the topic that they can easily reference in their clinical practice or research.

show abstract

Antiangiogenic Activity of Orally Absorbable Heparin Derivative in Different Types of Cancer Cells

Abstract: Our study shows that LHD has potent anticancer and antiangiogenic effect on at least three kinds of tumor cells. LHD can be specifically used for preventing neovascularization in tumor tissue because it has therapeutical potential as an antiangiogenic drug and can be orally absorbed.

Cited by 22 publications

References 41 publications

Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications

Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications

Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor

Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy

Contact Info

Product

Resources

About